MedTrace Logo

A Cross-sectional Study on the Association of Peptidoglycan Fragments Derived From Gut Microbiota With Alcohol Liver Disease

NCT07284862 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2025-12-16

No results posted yet for this study

Summary

alcohol-associated liver disease (ALD) is a leading cause of cirrhosis, yet the role of gut microbiota-derived peptidoglycan (PG) metabolites in liver injury remains unclear. This study aimed to elucidate the role of microbial DL-endopeptidases, which generate NOD2 ligands, in modulating alcohol-induced liver injury.Participants will provide stool samples.

Conditions

  • Alcohol-associated Liver Disease

Interventions

OTHER

An observational, non-interventional study design.

An observational, non-interventional study design.

Sponsors & Collaborators

  • Zhujiang Hospital

    lead OTHER

Principal Investigators

  • Xiaolong He, xiaolong · Southern Medical University, China

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-07-01
Primary Completion
2025-11-01
Completion
2025-11-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07284862 on ClinicalTrials.gov